相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名:
YAP1 单克隆抗体(兔源)
- 抗体英文名:
YAP1 Antibody, mAb, Rabbit
- 靶点:
YAP1
- 浓度:
0.5mg/mL(常规浓度,以官方说明书为准)
- 应用范围:
Western Blot、免疫细胞化学 / 免疫荧光 (ICC/IF)、免疫组化 (IHC)、免疫沉淀 (IP)
- 宿主:
兔(Rabbit)
- 适应物种:
人、小鼠、大鼠
- 保质期:
- 20℃可稳定保存 半 年
- 抗原来源:
人 YAP1 来源合成肽
- 级别:
科研级
- 库存:
现货
- 供应商:
上海经科化学科技有限公司
- 标记物:
无(Unconjugated)
- 克隆性:
单克隆(Monoclonal)
- 保存条件:
-20℃,可稳定保存 半 年
- 形态:
液体(Liquid)
- 亚型:
Rabbit IgG
- 免疫原:
人 YAP1 来源合成肽
- 规格:
50μl/100μl
| 规格: | 50μl | 产品价格: | ¥1200.0 |
|---|---|---|---|
| 规格: | 100μl | 产品价格: | ¥2200.0 |
| Specificity | This product is specific to YAP1 |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human YAP1 |
| Species Reactivity | Human |
| Conjugate | Unconjugated |
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
| Target Background | Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signaling pathway, crucial for organ size control and tumor suppression by restricting proliferation and promoting apoptosis.The Hippo signaling pathway core involves a kinase cascade featuring STK3/MST2 and STK4/MST1, along with its regulatory partner SAV1, which phosphorylates and activates LATS1/2 in complex with their regulatory protein, MOB1. This activation leads to the phosphorylation and inactivation of the YAP1 oncoprotein and WWTR1/TAZ. |
| Synonyms | 65 kDa Yes-associated protein; YAP1; YAP65; |
YAP1 抗体、Yes 相关蛋白 1 抗体、兔源 YAP1 抗体、单克隆 YAP1 抗体、抗 YAP1 抗体、细胞信号相关抗体、Hippo 信号通路相关抗体、肿瘤相关抗体、WB 抗体、IHC 抗体、IF 抗体、ELISA 抗体
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验STM:广州医科大学刘铭/谢茂彬合作发现肝细胞癌的新潜在治疗靶点 Claudin 6
显示,CLDN6 可以稳定 YAP1,促进其核转位,从而活化 Hippo 通路。 IP 结果显示 CLDN6 与 YAP1 竞争性结合 TJP2 鉴于 CLDN6 是多次跨膜蛋白,但其不具有(或尚未发现?)配体结合结构域,难以设计小分子药物;而如果使用单抗的话,由于肝细胞癌具有复杂的微环境, T 细胞难以发挥足够的抗体依赖细胞毒性(ADCC)效应杀伤癌细胞。因此,作者设计了靶向 CLDN6 的抗体偶联药物(Antibody-Drug Conjugate, ADC),将细胞毒性药物 DM1 和 CLDN6 抗体
技术资料







